File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/s41392-022-01103-x
- Scopus: eid_2-s2.0-85136866821
- WOS: WOS:000846790700001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjog̈ren’s syndrome
| Title | Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjog̈ren’s syndrome |
|---|---|
| Authors | |
| Issue Date | 29-Aug-2022 |
| Publisher | Springer Nature |
| Citation | Signal transduction and targeted therapy, 2022, v. 7, n. 1 How to Cite? |
| Abstract | Primary Sjogren's syndrome (pSS) is an autoimmune disease characterized by dry eyes and dry mouth caused by glandular inflammation in salivary glands (SG) and lacrimal glands. Currently, pSS patients are suffering from a lack of effective therapies. Many studies have revealed dysregulated immune responses during pSS development, in which Th17 cells are considered as the key driver in disease initiation and perpetuation.1,2 Previous studies suggested that artesunate (ART), an important derivative of artemisinin and a first-line antimalarial agent, modulated Th17 and regulatory T (Treg) cells balance in rats with collagen-induced arthritis. |
| Persistent Identifier | http://hdl.handle.net/10722/333969 |
| ISSN | 2023 Impact Factor: 40.8 2023 SCImago Journal Rankings: 8.737 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Xiao, Fan | - |
| dc.contributor.author | Rui, Ke | - |
| dc.contributor.author | Han, Man | - |
| dc.contributor.author | Zou, Liyun | - |
| dc.contributor.author | Huang, Enyu | - |
| dc.contributor.author | Tian, Jie | - |
| dc.contributor.author | Zhang, Lijun | - |
| dc.contributor.author | Jiang, Quan | - |
| dc.contributor.author | Wu, Yuzhang | - |
| dc.contributor.author | Lu, Liwei | - |
| dc.date.accessioned | 2023-10-10T03:15:02Z | - |
| dc.date.available | 2023-10-10T03:15:02Z | - |
| dc.date.issued | 2022-08-29 | - |
| dc.identifier.citation | Signal transduction and targeted therapy, 2022, v. 7, n. 1 | - |
| dc.identifier.issn | 2095-9907 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/333969 | - |
| dc.description.abstract | <p>Primary Sjogren's syndrome (pSS) is an autoimmune disease characterized by dry eyes and dry mouth caused by glandular inflammation in salivary glands (SG) and lacrimal glands. Currently, pSS patients are suffering from a lack of effective therapies. Many studies have revealed dysregulated immune responses during pSS development, in which Th17 cells are considered as the key driver in disease initiation and perpetuation.1,2 Previous studies suggested that artesunate (ART), an important derivative of artemisinin and a first-line antimalarial agent, modulated Th17 and regulatory T (Treg) cells balance in rats with collagen-induced arthritis.<br></p> | - |
| dc.language | eng | - |
| dc.publisher | Springer Nature | - |
| dc.relation.ispartof | Signal transduction and targeted therapy | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.title | Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjog̈ren’s syndrome | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1038/s41392-022-01103-x | - |
| dc.identifier.scopus | eid_2-s2.0-85136866821 | - |
| dc.identifier.volume | 7 | - |
| dc.identifier.issue | 1 | - |
| dc.identifier.isi | WOS:000846790700001 | - |
| dc.identifier.issnl | 2059-3635 | - |